Please select the eligibility criteria that correspond to the clinical trial below.
Title: Benefits and Risks of Early Antiretroviral Therapy in HIV-infected Adults in Abidjan, Côte d'Ivoire: Randomized Controlled Trial (ANRS 12136 TEMPRANO)
Brief Summary: The Temprano trial is based on the following assumptions:

* ART initiation at CD4 counts \<800/mm3 could significantly reduce the probability of severe HIV-related morbidity or death in the medium term.
* Tuberculosis and tuberculosis-related deaths are likely to represent a considerable proportion of morbidity and mortality among HIV-infected patients with high CD4 counts in sub-Saharan Africa. Therefore, 6-month Isoniazide Prophylaxis for Tuberculosis (IPT) and early ART could enhance each others efficacy.


Options:
A: Inclusion Criteria:

* HIV-1 or HIV-1 + HIV-2 infection
* Age \>18 years
* No ongoing active tuberculosis
* Home address in any district of the greater Abidjan area
* Written informed consent before any clinic visit or laboratory test
* Clinical and immunologic status:CD4 counts \<800/mm3 and no criteria for starting ART according to the most recent WHO guidelines

Exclusion Criteria:

* Pregnant or breastfeeding women
* HIV-2 infection alone
* Clinical signs suggesting a severe disease (including tuberculosis) that has not yet been diagnosed, such as fever, wasting, diarrhea or unexplained cough (partial list)
* Previous ART initiation
* Known severe renal, cardiac or hepatic disease
B: Inclusion Criteria:

Participating individuals must:

1. Be at least 18 years old
2. Be an inpatient or outpatient seeking care in study hospitals
3. Test positive on an initial EIA HIV screen
4. Have local residency or intent to live in study area for at least 90 days

Exclusion Criteria:

Individuals will be excluded from study participation if they:

1. Do not meet any one or more of the above inclusion criteria
2. Test result negative on initial EIA HIV screen
3. Have previously received confirmation on HIV infection in the study hospital or in any other setting (e.g., CDC clinic, infectious disease hospital, sub-county-level hospital)
4. Are prisoners or detainees at the time of initial screening
5. Are pregnant women (pregnant women are subject to mandatory testing)
C: Inclusion Criteria:

* HIV-infected.
* Confirmed or probable TB (more information on the criterion can be found in the protocol).
* Chest x-ray within 30 days prior to study entry.
* Receipt of 1-14 cumulative days of rifampin- or other rifamycin-based TB treatment that was initiated within 28 days prior to study entry.
* CD4 count less than 250 cells/mm\^3 within 30 days prior to study entry.
* Willing to use acceptable methods of contraception while on study drugs and for 6 weeks after stopping these drugs.
* Able to swallow oral medications.
* Parent of guardian willing to provide informed consent, if applicable.
* Karnofsky performance score =\>20 at time of study entry.

Exclusion Criteria:

* ART for longer than 7 cumulative days prior to study entry or treatment for any period of time with one or more antiretrovirals. Participants who have taken ART during pregnancy or for occupational exposure are not excluded.
* Allergy or sensitivity to any of the study drugs or their formulations.
* History of multidrug-resistant TB.
* Receipt of any investigational therapy or chemotherapy within 30 days prior to study entry.
* Certain medications.
* Breastfeeding.
D: Inclusion Criteria:

* HIV infection newly diagnosed during community-based HTC-campaigns
* Never been on triple-ART
* Lives and/or works in the district of Butha-Buthe and declares to seek follow-up at one of the 6 health facilities involved in the study
* Signed written informed consent

Exclusion Criteria:

* Pregnant or breast-feeding
* Already enrolled in chronic care for another disease, such as tuberculosis or diabetes
* Clinical WHO-stage 4 or active tuberculosis
* Positive cryptococcal antigen test

Answer: A